As of 2025-04-19, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -2.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 290.34 mil USD. EYPT's TTM EBITDA according to its financial statements is -144.31 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 8.5x | 7.7x |
| Forward P/E multiples | 8.5x - 15.3x | 11.4x |
| Fair Price | (16.31) - (16.31) | (18.60) |
| Upside | -387.5% - -387.5% | -427.8% |
| Date | EV/EBITDA |
| 2025-04-11 | -1.87 |
| 2025-04-10 | -1.60 |
| 2025-04-09 | -1.49 |
| 2025-04-08 | -1.28 |
| 2025-04-07 | -1.51 |
| 2025-04-04 | -1.50 |
| 2025-04-03 | -1.69 |
| 2025-04-02 | -1.87 |
| 2025-04-01 | -1.71 |
| 2025-03-31 | -1.89 |
| 2025-03-28 | -2.09 |
| 2025-03-27 | -2.12 |
| 2025-03-26 | -2.20 |
| 2025-03-25 | -2.28 |
| 2025-03-24 | -2.33 |
| 2025-03-21 | -2.29 |
| 2025-03-20 | -2.21 |
| 2025-03-19 | -2.26 |
| 2025-03-18 | -2.27 |
| 2025-03-17 | -2.47 |
| 2025-03-14 | -2.41 |
| 2025-03-13 | -2.56 |
| 2025-03-12 | -2.80 |
| 2025-03-11 | -2.81 |
| 2025-03-10 | -2.69 |
| 2025-03-07 | -2.70 |
| 2025-03-06 | -2.56 |
| 2025-03-05 | -2.44 |
| 2025-03-04 | -2.20 |
| 2025-03-03 | -2.03 |
| 2025-02-28 | -2.30 |
| 2025-02-27 | -2.28 |
| 2025-02-26 | -2.12 |
| 2025-02-25 | -2.15 |
| 2025-02-24 | -2.12 |
| 2025-02-21 | -2.24 |
| 2025-02-20 | -2.33 |
| 2025-02-19 | -2.39 |
| 2025-02-18 | -2.42 |
| 2025-02-14 | -2.40 |
| 2025-02-13 | -2.31 |
| 2025-02-12 | -2.33 |
| 2025-02-11 | -2.30 |
| 2025-02-10 | -2.30 |
| 2025-02-07 | -2.40 |
| 2025-02-06 | -2.46 |
| 2025-02-05 | -3.02 |
| 2025-02-04 | -2.94 |
| 2025-02-03 | -2.72 |
| 2025-01-31 | -2.95 |